Immuneering Corp Cash Flow Conversion Efficiency
Immuneering Corp cash flow conversion efficiency. Based on the latest financial reports, Immuneering Corp (IMRX) has a cash flow conversion efficiency ratio of -0.053x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.98 Million) by net assets ($227.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Immuneering Corp (2019–2024)
Cash flow conversion efficiency of Immuneering Corp from 2019 to 2024. This chart illustrates how Immuneering Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Immuneering Corp share price for real-time trading data and today's change.
Immuneering Corp Cash Flow Conversion Ratio Explained
Immuneering Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Immuneering Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immuneering Corp ranked by their cash flow conversion efficiency. Also see Immuneering Corp market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Third Harmonic Bio Inc.
NASDAQ:THRD
|
-0.049x |
|
Lanzhou Zhuangyuan Pasture Co Ltd
SHE:002910
|
0.059x |
|
Eisen- und Hüttenwerke AG
F:EIS
|
-0.010x |
|
Jena Acquisition Corporation II
NYSE:JENA
|
-0.001x |
|
ODFJELL TECHNOLOGYLTD
F:ND4
|
0.302x |
|
KS Terminals Inc
TW:3003
|
-0.007x |
|
Trigold Holdings Ltd
TWO:3709
|
-0.318x |
|
Cogelec SA
PA:ALLEC
|
0.282x |
Annual Cash Flow Conversion Efficiency for Immuneering Corp (2019–2024)
The table below shows the annual cash flow conversion efficiency of Immuneering Corp from 2019 to 2024. Review Immuneering Corp leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $41.39 Million | $-55.00 Million | -1.329x | -145.81% |
| 2023-12-31 | $90.58 Million | $-48.97 Million | -0.541x | -34.66% |
| 2022-12-31 | $109.85 Million | $-44.10 Million | -0.401x | -102.98% |
| 2021-12-31 | $155.98 Million | $-30.85 Million | -0.198x | -130.41% |
| 2020-12-31 | $-22.48 Million | $-14.62 Million | 0.650x | -4.43% |
| 2019-12-31 | $-6.53 Million | $-4.44 Million | 0.680x | -- |
About Immuneering Corp
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 … Read more